Last month I evaluated two AIM-quoted Chinese companies for members of the Motley Fool’s Champion Shares service. I concluded the duo were “good examples of growth shares I’d avoid”, adding “both companies have demonstrated rapid expansion of late, but a complete absence of cash generation does not suggest these businesses are built on firm foundations.”
One of the shares I looked at was Bodisen Biotech (LSE: BODI), which has since collapsed 47%.*…